Global Group A and Group C Meningococcal Polysaccharide Vaccine Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global Group A and Group C Meningococcal Polysaccharide Vaccine market size was valued at USD 293.3 million in 2022 and is forecast to a readjusted size of USD 430.2 million by 2029 with a CAGR of 5.6% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Meningococcal disease, caused by Neisseria meningitidis, can cause serious illness and even death. The global burden of meningococcal disease, especially serogroups A and C, drives the need for effective vaccines to prevent these infections.
After vaccination, the body can produce a humoral immune response. It is used to prevent infectious diseases caused by group A and group C meningococci, such as cerebrospinal meningitis and pneumonia.
This report is a detailed and comprehensive analysis for global Group A and Group C Meningococcal Polysaccharide Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Group A and Group C Meningococcal Polysaccharide Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Group A and Group C Meningococcal Polysaccharide Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Group A and Group C Meningococcal Polysaccharide Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Group A and Group C Meningococcal Polysaccharide Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Group A and Group C Meningococcal Polysaccharide Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Group A and Group C Meningococcal Polysaccharide Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Walvax, Lanzhou Institute of Biological Products, AIM Bio, Sanofi Pasteur and GSK, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Group A and Group C Meningococcal Polysaccharide Vaccine market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Group A and Group C Meningococcal Polysaccharide Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Group A and Group C Meningococcal Polysaccharide Vaccine, with price, sales, revenue and global market share of Group A and Group C Meningococcal Polysaccharide Vaccine from 2018 to 2023.
Chapter 3, the Group A and Group C Meningococcal Polysaccharide Vaccine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Group A and Group C Meningococcal Polysaccharide Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Group A and Group C Meningococcal Polysaccharide Vaccine market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Group A and Group C Meningococcal Polysaccharide Vaccine.
Chapter 14 and 15, to describe Group A and Group C Meningococcal Polysaccharide Vaccine sales channel, distributors, customers, research findings and conclusion.
Meningococcal disease, caused by Neisseria meningitidis, can cause serious illness and even death. The global burden of meningococcal disease, especially serogroups A and C, drives the need for effective vaccines to prevent these infections.
After vaccination, the body can produce a humoral immune response. It is used to prevent infectious diseases caused by group A and group C meningococci, such as cerebrospinal meningitis and pneumonia.
This report is a detailed and comprehensive analysis for global Group A and Group C Meningococcal Polysaccharide Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Group A and Group C Meningococcal Polysaccharide Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Group A and Group C Meningococcal Polysaccharide Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Group A and Group C Meningococcal Polysaccharide Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Group A and Group C Meningococcal Polysaccharide Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Group A and Group C Meningococcal Polysaccharide Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Group A and Group C Meningococcal Polysaccharide Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Walvax, Lanzhou Institute of Biological Products, AIM Bio, Sanofi Pasteur and GSK, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Group A and Group C Meningococcal Polysaccharide Vaccine market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Class 1 Vaccine
- Class II Vaccine
- Hospital
- Clinic
- Walvax
- Lanzhou Institute of Biological Products
- AIM Bio
- Sanofi Pasteur
- GSK
- Hualan Bio
- ZFSW
- Changsheng
- Kanghua Bio
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Group A and Group C Meningococcal Polysaccharide Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Group A and Group C Meningococcal Polysaccharide Vaccine, with price, sales, revenue and global market share of Group A and Group C Meningococcal Polysaccharide Vaccine from 2018 to 2023.
Chapter 3, the Group A and Group C Meningococcal Polysaccharide Vaccine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Group A and Group C Meningococcal Polysaccharide Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Group A and Group C Meningococcal Polysaccharide Vaccine market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Group A and Group C Meningococcal Polysaccharide Vaccine.
Chapter 14 and 15, to describe Group A and Group C Meningococcal Polysaccharide Vaccine sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Group A and Group C Meningococcal Polysaccharide Vaccine
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Class 1 Vaccine
1.3.3 Class II Vaccine
1.4 Market Analysis by Application
1.4.1 Overview: Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.5 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Size & Forecast
1.5.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (2018-2029)
1.5.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 Walvax
2.1.1 Walvax Details
2.1.2 Walvax Major Business
2.1.3 Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
2.1.4 Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Walvax Recent Developments/Updates
2.2 Lanzhou Institute of Biological Products
2.2.1 Lanzhou Institute of Biological Products Details
2.2.2 Lanzhou Institute of Biological Products Major Business
2.2.3 Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
2.2.4 Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Lanzhou Institute of Biological Products Recent Developments/Updates
2.3 AIM Bio
2.3.1 AIM Bio Details
2.3.2 AIM Bio Major Business
2.3.3 AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
2.3.4 AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 AIM Bio Recent Developments/Updates
2.4 Sanofi Pasteur
2.4.1 Sanofi Pasteur Details
2.4.2 Sanofi Pasteur Major Business
2.4.3 Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
2.4.4 Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Sanofi Pasteur Recent Developments/Updates
2.5 GSK
2.5.1 GSK Details
2.5.2 GSK Major Business
2.5.3 GSK Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
2.5.4 GSK Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 GSK Recent Developments/Updates
2.6 Hualan Bio
2.6.1 Hualan Bio Details
2.6.2 Hualan Bio Major Business
2.6.3 Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
2.6.4 Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Hualan Bio Recent Developments/Updates
2.7 ZFSW
2.7.1 ZFSW Details
2.7.2 ZFSW Major Business
2.7.3 ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
2.7.4 ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 ZFSW Recent Developments/Updates
2.8 Changsheng
2.8.1 Changsheng Details
2.8.2 Changsheng Major Business
2.8.3 Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
2.8.4 Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Changsheng Recent Developments/Updates
2.9 Kanghua Bio
2.9.1 Kanghua Bio Details
2.9.2 Kanghua Bio Major Business
2.9.3 Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
2.9.4 Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Kanghua Bio Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: GROUP A AND GROUP C MENINGOCOCCAL POLYSACCHARIDE VACCINE BY MANUFACTURER
3.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Manufacturer (2018-2023)
3.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Manufacturer (2018-2023)
3.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Group A and Group C Meningococcal Polysaccharide Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturer Market Share in 2022
3.4.2 Top 6 Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturer Market Share in 2022
3.5 Group A and Group C Meningococcal Polysaccharide Vaccine Market: Overall Company Footprint Analysis
3.5.1 Group A and Group C Meningococcal Polysaccharide Vaccine Market: Region Footprint
3.5.2 Group A and Group C Meningococcal Polysaccharide Vaccine Market: Company Product Type Footprint
3.5.3 Group A and Group C Meningococcal Polysaccharide Vaccine Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Region
4.1.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2018-2029)
4.1.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2018-2029)
4.1.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Region (2018-2029)
4.2 North America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2018-2029)
4.3 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2018-2029)
4.4 Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2018-2029)
4.5 South America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2018-2029)
4.6 Middle East and Africa Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2018-2029)
5.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Type (2018-2029)
5.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2018-2029)
6.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Application (2018-2029)
6.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2018-2029)
7.2 North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2018-2029)
7.3 North America Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country
7.3.1 North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2018-2029)
7.3.2 North America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2018-2029)
8.2 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2018-2029)
8.3 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country
8.3.1 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2018-2029)
8.3.2 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Region
9.3.1 Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2018-2029)
10.2 South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2018-2029)
10.3 South America Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country
10.3.1 South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2018-2029)
10.3.2 South America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country
11.3.1 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 Group A and Group C Meningococcal Polysaccharide Vaccine Market Drivers
12.2 Group A and Group C Meningococcal Polysaccharide Vaccine Market Restraints
12.3 Group A and Group C Meningococcal Polysaccharide Vaccine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Group A and Group C Meningococcal Polysaccharide Vaccine and Key Manufacturers
13.2 Manufacturing Costs Percentage of Group A and Group C Meningococcal Polysaccharide Vaccine
13.3 Group A and Group C Meningococcal Polysaccharide Vaccine Production Process
13.4 Group A and Group C Meningococcal Polysaccharide Vaccine Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Group A and Group C Meningococcal Polysaccharide Vaccine Typical Distributors
14.3 Group A and Group C Meningococcal Polysaccharide Vaccine Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of Group A and Group C Meningococcal Polysaccharide Vaccine
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Class 1 Vaccine
1.3.3 Class II Vaccine
1.4 Market Analysis by Application
1.4.1 Overview: Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.5 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Size & Forecast
1.5.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (2018-2029)
1.5.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 Walvax
2.1.1 Walvax Details
2.1.2 Walvax Major Business
2.1.3 Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
2.1.4 Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Walvax Recent Developments/Updates
2.2 Lanzhou Institute of Biological Products
2.2.1 Lanzhou Institute of Biological Products Details
2.2.2 Lanzhou Institute of Biological Products Major Business
2.2.3 Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
2.2.4 Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Lanzhou Institute of Biological Products Recent Developments/Updates
2.3 AIM Bio
2.3.1 AIM Bio Details
2.3.2 AIM Bio Major Business
2.3.3 AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
2.3.4 AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 AIM Bio Recent Developments/Updates
2.4 Sanofi Pasteur
2.4.1 Sanofi Pasteur Details
2.4.2 Sanofi Pasteur Major Business
2.4.3 Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
2.4.4 Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Sanofi Pasteur Recent Developments/Updates
2.5 GSK
2.5.1 GSK Details
2.5.2 GSK Major Business
2.5.3 GSK Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
2.5.4 GSK Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 GSK Recent Developments/Updates
2.6 Hualan Bio
2.6.1 Hualan Bio Details
2.6.2 Hualan Bio Major Business
2.6.3 Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
2.6.4 Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Hualan Bio Recent Developments/Updates
2.7 ZFSW
2.7.1 ZFSW Details
2.7.2 ZFSW Major Business
2.7.3 ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
2.7.4 ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 ZFSW Recent Developments/Updates
2.8 Changsheng
2.8.1 Changsheng Details
2.8.2 Changsheng Major Business
2.8.3 Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
2.8.4 Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Changsheng Recent Developments/Updates
2.9 Kanghua Bio
2.9.1 Kanghua Bio Details
2.9.2 Kanghua Bio Major Business
2.9.3 Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
2.9.4 Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Kanghua Bio Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: GROUP A AND GROUP C MENINGOCOCCAL POLYSACCHARIDE VACCINE BY MANUFACTURER
3.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Manufacturer (2018-2023)
3.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Manufacturer (2018-2023)
3.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Group A and Group C Meningococcal Polysaccharide Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturer Market Share in 2022
3.4.2 Top 6 Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturer Market Share in 2022
3.5 Group A and Group C Meningococcal Polysaccharide Vaccine Market: Overall Company Footprint Analysis
3.5.1 Group A and Group C Meningococcal Polysaccharide Vaccine Market: Region Footprint
3.5.2 Group A and Group C Meningococcal Polysaccharide Vaccine Market: Company Product Type Footprint
3.5.3 Group A and Group C Meningococcal Polysaccharide Vaccine Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Region
4.1.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2018-2029)
4.1.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2018-2029)
4.1.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Region (2018-2029)
4.2 North America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2018-2029)
4.3 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2018-2029)
4.4 Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2018-2029)
4.5 South America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2018-2029)
4.6 Middle East and Africa Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2018-2029)
5.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Type (2018-2029)
5.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2018-2029)
6.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Application (2018-2029)
6.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2018-2029)
7.2 North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2018-2029)
7.3 North America Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country
7.3.1 North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2018-2029)
7.3.2 North America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2018-2029)
8.2 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2018-2029)
8.3 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country
8.3.1 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2018-2029)
8.3.2 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Region
9.3.1 Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2018-2029)
10.2 South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2018-2029)
10.3 South America Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country
10.3.1 South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2018-2029)
10.3.2 South America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country
11.3.1 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 Group A and Group C Meningococcal Polysaccharide Vaccine Market Drivers
12.2 Group A and Group C Meningococcal Polysaccharide Vaccine Market Restraints
12.3 Group A and Group C Meningococcal Polysaccharide Vaccine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Group A and Group C Meningococcal Polysaccharide Vaccine and Key Manufacturers
13.2 Manufacturing Costs Percentage of Group A and Group C Meningococcal Polysaccharide Vaccine
13.3 Group A and Group C Meningococcal Polysaccharide Vaccine Production Process
13.4 Group A and Group C Meningococcal Polysaccharide Vaccine Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Group A and Group C Meningococcal Polysaccharide Vaccine Typical Distributors
14.3 Group A and Group C Meningococcal Polysaccharide Vaccine Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Walvax Basic Information, Manufacturing Base and Competitors
Table 4. Walvax Major Business
Table 5. Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
Table 6. Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Walvax Recent Developments/Updates
Table 8. Lanzhou Institute of Biological Products Basic Information, Manufacturing Base and Competitors
Table 9. Lanzhou Institute of Biological Products Major Business
Table 10. Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
Table 11. Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Lanzhou Institute of Biological Products Recent Developments/Updates
Table 13. AIM Bio Basic Information, Manufacturing Base and Competitors
Table 14. AIM Bio Major Business
Table 15. AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
Table 16. AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. AIM Bio Recent Developments/Updates
Table 18. Sanofi Pasteur Basic Information, Manufacturing Base and Competitors
Table 19. Sanofi Pasteur Major Business
Table 20. Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
Table 21. Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Sanofi Pasteur Recent Developments/Updates
Table 23. GSK Basic Information, Manufacturing Base and Competitors
Table 24. GSK Major Business
Table 25. GSK Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
Table 26. GSK Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. GSK Recent Developments/Updates
Table 28. Hualan Bio Basic Information, Manufacturing Base and Competitors
Table 29. Hualan Bio Major Business
Table 30. Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
Table 31. Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Hualan Bio Recent Developments/Updates
Table 33. ZFSW Basic Information, Manufacturing Base and Competitors
Table 34. ZFSW Major Business
Table 35. ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
Table 36. ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. ZFSW Recent Developments/Updates
Table 38. Changsheng Basic Information, Manufacturing Base and Competitors
Table 39. Changsheng Major Business
Table 40. Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
Table 41. Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Changsheng Recent Developments/Updates
Table 43. Kanghua Bio Basic Information, Manufacturing Base and Competitors
Table 44. Kanghua Bio Major Business
Table 45. Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
Table 46. Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Kanghua Bio Recent Developments/Updates
Table 48. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 49. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Manufacturer (2018-2023) & (USD Million)
Table 50. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 51. Market Position of Manufacturers in Group A and Group C Meningococcal Polysaccharide Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 52. Head Office and Group A and Group C Meningococcal Polysaccharide Vaccine Production Site of Key Manufacturer
Table 53. Group A and Group C Meningococcal Polysaccharide Vaccine Market: Company Product Type Footprint
Table 54. Group A and Group C Meningococcal Polysaccharide Vaccine Market: Company Product Application Footprint
Table 55. Group A and Group C Meningococcal Polysaccharide Vaccine New Market Entrants and Barriers to Market Entry
Table 56. Group A and Group C Meningococcal Polysaccharide Vaccine Mergers, Acquisition, Agreements, and Collaborations
Table 57. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2018-2023) & (K Units)
Table 58. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2024-2029) & (K Units)
Table 59. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 60. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 61. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Region (2018-2023) & (US$/Unit)
Table 62. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Region (2024-2029) & (US$/Unit)
Table 63. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 64. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 65. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Type (2018-2023) & (USD Million)
Table 66. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Type (2024-2029) & (USD Million)
Table 67. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Type (2018-2023) & (US$/Unit)
Table 68. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Type (2024-2029) & (US$/Unit)
Table 69. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 70. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 71. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Application (2018-2023) & (USD Million)
Table 72. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Application (2024-2029) & (USD Million)
Table 73. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Application (2018-2023) & (US$/Unit)
Table 74. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Application (2024-2029) & (US$/Unit)
Table 75. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 76. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 77. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 78. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 79. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2018-2023) & (K Units)
Table 80. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2024-2029) & (K Units)
Table 81. North America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 82. North America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 83. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 84. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 85. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 86. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 87. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2018-2023) & (K Units)
Table 88. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2024-2029) & (K Units)
Table 89. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 90. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 91. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 92. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 93. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 94. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 95. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2018-2023) & (K Units)
Table 96. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2024-2029) & (K Units)
Table 97. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 98. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 99. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 100. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 101. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 102. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 103. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2018-2023) & (K Units)
Table 104. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2024-2029) & (K Units)
Table 105. South America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 106. South America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 107. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 108. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 109. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 110. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 111. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2018-2023) & (K Units)
Table 112. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2024-2029) & (K Units)
Table 113. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 114. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 115. Group A and Group C Meningococcal Polysaccharide Vaccine Raw Material
Table 116. Key Manufacturers of Group A and Group C Meningococcal Polysaccharide Vaccine Raw Materials
Table 117. Group A and Group C Meningococcal Polysaccharide Vaccine Typical Distributors
Table 118. Group A and Group C Meningococcal Polysaccharide Vaccine Typical Customers
Table 1. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Walvax Basic Information, Manufacturing Base and Competitors
Table 4. Walvax Major Business
Table 5. Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
Table 6. Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Walvax Recent Developments/Updates
Table 8. Lanzhou Institute of Biological Products Basic Information, Manufacturing Base and Competitors
Table 9. Lanzhou Institute of Biological Products Major Business
Table 10. Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
Table 11. Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Lanzhou Institute of Biological Products Recent Developments/Updates
Table 13. AIM Bio Basic Information, Manufacturing Base and Competitors
Table 14. AIM Bio Major Business
Table 15. AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
Table 16. AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. AIM Bio Recent Developments/Updates
Table 18. Sanofi Pasteur Basic Information, Manufacturing Base and Competitors
Table 19. Sanofi Pasteur Major Business
Table 20. Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
Table 21. Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Sanofi Pasteur Recent Developments/Updates
Table 23. GSK Basic Information, Manufacturing Base and Competitors
Table 24. GSK Major Business
Table 25. GSK Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
Table 26. GSK Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. GSK Recent Developments/Updates
Table 28. Hualan Bio Basic Information, Manufacturing Base and Competitors
Table 29. Hualan Bio Major Business
Table 30. Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
Table 31. Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Hualan Bio Recent Developments/Updates
Table 33. ZFSW Basic Information, Manufacturing Base and Competitors
Table 34. ZFSW Major Business
Table 35. ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
Table 36. ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. ZFSW Recent Developments/Updates
Table 38. Changsheng Basic Information, Manufacturing Base and Competitors
Table 39. Changsheng Major Business
Table 40. Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
Table 41. Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Changsheng Recent Developments/Updates
Table 43. Kanghua Bio Basic Information, Manufacturing Base and Competitors
Table 44. Kanghua Bio Major Business
Table 45. Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product and Services
Table 46. Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Kanghua Bio Recent Developments/Updates
Table 48. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 49. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Manufacturer (2018-2023) & (USD Million)
Table 50. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 51. Market Position of Manufacturers in Group A and Group C Meningococcal Polysaccharide Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 52. Head Office and Group A and Group C Meningococcal Polysaccharide Vaccine Production Site of Key Manufacturer
Table 53. Group A and Group C Meningococcal Polysaccharide Vaccine Market: Company Product Type Footprint
Table 54. Group A and Group C Meningococcal Polysaccharide Vaccine Market: Company Product Application Footprint
Table 55. Group A and Group C Meningococcal Polysaccharide Vaccine New Market Entrants and Barriers to Market Entry
Table 56. Group A and Group C Meningococcal Polysaccharide Vaccine Mergers, Acquisition, Agreements, and Collaborations
Table 57. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2018-2023) & (K Units)
Table 58. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2024-2029) & (K Units)
Table 59. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 60. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 61. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Region (2018-2023) & (US$/Unit)
Table 62. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Region (2024-2029) & (US$/Unit)
Table 63. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 64. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 65. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Type (2018-2023) & (USD Million)
Table 66. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Type (2024-2029) & (USD Million)
Table 67. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Type (2018-2023) & (US$/Unit)
Table 68. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Type (2024-2029) & (US$/Unit)
Table 69. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 70. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 71. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Application (2018-2023) & (USD Million)
Table 72. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Application (2024-2029) & (USD Million)
Table 73. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Application (2018-2023) & (US$/Unit)
Table 74. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Application (2024-2029) & (US$/Unit)
Table 75. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 76. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 77. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 78. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 79. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2018-2023) & (K Units)
Table 80. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2024-2029) & (K Units)
Table 81. North America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 82. North America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 83. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 84. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 85. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 86. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 87. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2018-2023) & (K Units)
Table 88. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2024-2029) & (K Units)
Table 89. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 90. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 91. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 92. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 93. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 94. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 95. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2018-2023) & (K Units)
Table 96. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2024-2029) & (K Units)
Table 97. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 98. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 99. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 100. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 101. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 102. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 103. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2018-2023) & (K Units)
Table 104. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Country (2024-2029) & (K Units)
Table 105. South America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 106. South America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 107. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 108. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 109. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 110. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 111. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2018-2023) & (K Units)
Table 112. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity by Region (2024-2029) & (K Units)
Table 113. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 114. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 115. Group A and Group C Meningococcal Polysaccharide Vaccine Raw Material
Table 116. Key Manufacturers of Group A and Group C Meningococcal Polysaccharide Vaccine Raw Materials
Table 117. Group A and Group C Meningococcal Polysaccharide Vaccine Typical Distributors
Table 118. Group A and Group C Meningococcal Polysaccharide Vaccine Typical Customers
LIST OF FIGURES
Figure 1. Group A and Group C Meningococcal Polysaccharide Vaccine Picture
Figure 2. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Type in 2022
Figure 4. Class 1 Vaccine Examples
Figure 5. Class II Vaccine Examples
Figure 6. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 7. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Application in 2022
Figure 8. Hospital Examples
Figure 9. Clinic Examples
Figure 10. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 11. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 12. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (2018-2029) & (K Units)
Figure 13. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price (2018-2029) & (US$/Unit)
Figure 14. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Manufacturer in 2022
Figure 15. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Manufacturer in 2022
Figure 16. Producer Shipments of Group A and Group C Meningococcal Polysaccharide Vaccine by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 17. Top 3 Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturer (Consumption Value) Market Share in 2022
Figure 18. Top 6 Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturer (Consumption Value) Market Share in 2022
Figure 19. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 20. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 21. North America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 22. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 23. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 24. South America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 25. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 26. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 27. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Type (2018-2029)
Figure 28. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Type (2018-2029) & (US$/Unit)
Figure 29. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 30. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Application (2018-2029)
Figure 31. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Application (2018-2029) & (US$/Unit)
Figure 32. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 33. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 34. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 35. North America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 36. United States Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 37. Canada Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 38. Mexico Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 40. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 41. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 42. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 43. Germany Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 44. France Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. United Kingdom Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. Russia Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Italy Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 49. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 50. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 51. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 52. China Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 53. Japan Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Korea Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. India Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Southeast Asia Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Australia Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 59. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 60. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 61. South America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 62. Brazil Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 63. Argentina Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 65. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 66. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 67. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 68. Turkey Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 69. Egypt Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Saudi Arabia Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. South Africa Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Group A and Group C Meningococcal Polysaccharide Vaccine Market Drivers
Figure 73. Group A and Group C Meningococcal Polysaccharide Vaccine Market Restraints
Figure 74. Group A and Group C Meningococcal Polysaccharide Vaccine Market Trends
Figure 75. Porters Five Forces Analysis
Figure 76. Manufacturing Cost Structure Analysis of Group A and Group C Meningococcal Polysaccharide Vaccine in 2022
Figure 77. Manufacturing Process Analysis of Group A and Group C Meningococcal Polysaccharide Vaccine
Figure 78. Group A and Group C Meningococcal Polysaccharide Vaccine Industrial Chain
Figure 79. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 80. Direct Channel Pros & Cons
Figure 81. Indirect Channel Pros & Cons
Figure 82. Methodology
Figure 83. Research Process and Data Source
Figure 1. Group A and Group C Meningococcal Polysaccharide Vaccine Picture
Figure 2. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Type in 2022
Figure 4. Class 1 Vaccine Examples
Figure 5. Class II Vaccine Examples
Figure 6. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 7. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Application in 2022
Figure 8. Hospital Examples
Figure 9. Clinic Examples
Figure 10. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 11. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 12. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity (2018-2029) & (K Units)
Figure 13. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price (2018-2029) & (US$/Unit)
Figure 14. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Manufacturer in 2022
Figure 15. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Manufacturer in 2022
Figure 16. Producer Shipments of Group A and Group C Meningococcal Polysaccharide Vaccine by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 17. Top 3 Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturer (Consumption Value) Market Share in 2022
Figure 18. Top 6 Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturer (Consumption Value) Market Share in 2022
Figure 19. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 20. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 21. North America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 22. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 23. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 24. South America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 25. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 26. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 27. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Type (2018-2029)
Figure 28. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Type (2018-2029) & (US$/Unit)
Figure 29. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 30. Global Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Application (2018-2029)
Figure 31. Global Group A and Group C Meningococcal Polysaccharide Vaccine Average Price by Application (2018-2029) & (US$/Unit)
Figure 32. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 33. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 34. North America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 35. North America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 36. United States Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 37. Canada Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 38. Mexico Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 40. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 41. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 42. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 43. Germany Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 44. France Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. United Kingdom Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. Russia Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Italy Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 49. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 50. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 51. Asia-Pacific Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 52. China Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 53. Japan Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Korea Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. India Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Southeast Asia Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Australia Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 59. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 60. South America Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 61. South America Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 62. Brazil Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 63. Argentina Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 65. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 66. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 67. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 68. Turkey Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 69. Egypt Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Saudi Arabia Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. South Africa Group A and Group C Meningococcal Polysaccharide Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Group A and Group C Meningococcal Polysaccharide Vaccine Market Drivers
Figure 73. Group A and Group C Meningococcal Polysaccharide Vaccine Market Restraints
Figure 74. Group A and Group C Meningococcal Polysaccharide Vaccine Market Trends
Figure 75. Porters Five Forces Analysis
Figure 76. Manufacturing Cost Structure Analysis of Group A and Group C Meningococcal Polysaccharide Vaccine in 2022
Figure 77. Manufacturing Process Analysis of Group A and Group C Meningococcal Polysaccharide Vaccine
Figure 78. Group A and Group C Meningococcal Polysaccharide Vaccine Industrial Chain
Figure 79. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 80. Direct Channel Pros & Cons
Figure 81. Indirect Channel Pros & Cons
Figure 82. Methodology
Figure 83. Research Process and Data Source
